MENU
LCTX
Stock ticker: ASE
PRICE
CHANGE
CAPITALIZATION
Lineage Cell Therapeutics (LCTX) Ownership - Who owns Lineage Cell Therapeutics?
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases... Show more
Profile
Industry
N/A
Address
2173 Salk Avenue
Phone
+1 442 287-8990
Employees
75
Web
https://www.lineagecell.com
Details
Group
Domestic Stock Funds
Category
Biotechnology
Capitalization
213.56M
P/E Ratio
N/A
Total Cash
47.91M
Projected Growth
N/A
Total Debt
2.24M
Revenue
9.56M
Risk (Beta)
1.42
Dividend Yield
N/A
Total Cash/Share
0.21
Total Debt/Equity
N/A
Revenue/Share
0.05 USD as % of share price
Fundamentals
LCTX
Capitalization
214M
P/E Ratio
N/A
Risk (Beta)
1.42
Dividend Yield
N/A
Total Cash
47.9M
Total Cash/Share
0.21
Total Debt
2.24M
Total Debt/Equity
N/A
Projected Growth (PEG Ratio)
N/A
Revenue/Share (as % of the share price)
0.05%
Revenue
9.56M
ROE
N/A
Book Value
79M
P/B Ratio
2.70
Cash Flow
N/A
Earnings
-0.07
Average Daily Volume YTD
N/A
Common Shares Outstanding - Security Level
489M
Current Ratio
3.82
Current Revenue Per Employee
19506.49
Dividends Per Share - Security
N/A
EBITDA
-20.72M
Float
N/A
Float - Current
N/A
Gross Income Margin
97.60
Revenue To Assets
-14.72
Shares Held By Institutions
64M
Shares Outstanding - Current
228M
Total Liabilities
34.1M
Total Volume MTD
N/A
Value
N/A
Gain YTD
86.109
View a ticker or compare two or three
VS
VS
Show more...
Interact to see
Advertisement
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information
General Information
a clinical-stage biotechnology company developing new cellular therapies for degenerative retinal diseases, and neurological conditions
Industry Biotechnology
Profile
Fundamentals
Details
Industry
N/A
Address
2173 Salk Avenue
Phone
+1 442 287-8990
Employees
75
Web
https://www.lineagecell.com